Novo Nordisk introduces the first Wegovy pill in the U.S.

Novo Nordisk has launched the first oral version of its GLP-1 medication, Wegovy, in the United States. The once-daily pill mimics the same appetite-regulating hormone as the injections that redefined obesity care — but without the needle.

A more accessible GLP-1

The new Wegovy pill starts at $149 per month for self-paying patients, compared to over $1,000 for most injectables. Novo says the pricing is part of a broader goal to make treatment more accessible to the 100 million Americans living with obesity.

The 1.5mg starting dose is now available across more than 70,000 pharmacies, including CVS and Costco, as well as through telehealth providers like Ro, LifeMD, and WeightWatchers. Higher doses up to 4mg will roll out later this week.

Designed for everyday life

The oral format eliminates the storage requirements and injection fatigue that cause many patients to discontinue GLP-1 therapy. By introducing a daily pill that integrates into existing routines, Novo aims to make adherence easier and long-term outcomes more sustainable.

Analysts note that the pill’s lower-than-expected price signals a new phase of competition — one centered on accessibility, convenience, and real-world adherence rather than exclusivity.

Where to find it

The Wegovy pill is available now at major pharmacies and select telehealth platforms for $149 per month. Higher doses will become available later this spring.